Obesity in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031

Obesity in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031

Summary

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the obesity market through 2031.

GlobalData estimates sales of obesity therapeutics to be approximately $10.5 billion across the 7MM in 2021. By 2031, GlobalData expects the obesity market to grow at a strong compound annual growth rate (CAGR) of 32.3%, reaching sales of $173.5 billion by the end of the forecast period.

Major drivers of growth in the obesity market during the forecast period include the following:

• There will be an increase in therapies with longer duration of action, such as Novo Nordisk’s Wegovy (semaglutide) and CagriSema (semaglutide + cagrilintide), Eli Lilly’s tirzepatide, retatrutide, and bimagrumab (BYM338), and Amgen’s MariTide, consequently improving patient compliance for obesity patients who may already experience a heavy treatment burden due to comorbid conditions.
• The diabetic population is set to grow in line with the increased prevalence of risk factors such as obesity.
• Therapies with new routes of administration will enter the market, such as Novo Nordisk’s oral

semaglutide (NN-9932), Eli Lilly’s orforglipron, Structure Therapeutics’ GSBR-1290, and other oral

agents with other mechanisms of actions, such as monlunabant and enobosarm.

Major barriers to growth in the obesity market during the forecast period will include the following:

• Expensive therapies will face reimbursement challenges in markets where cost-conscious decisions are increasingly implemented.
• Disease awareness is still an unmet need in the obesity space and many patients are still not offered pharmacotherapy, limiting medicine uptake.
• Shortages of blockbuster medications can disrupt patient treatment and drive patients to buy illegitimate versions of weight loss drugs, which is a risk both for patients and for the reputation of pharmaceutical companies.
• The expiry of established brands, such as Saxenda, leaves these products vulnerable to sales erosion.

Scope

• Overview of obesity, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized obesity therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the obesity therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for obesity treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global obesity therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM obesity therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM obesity therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Please note: this is delivered as a Zip file.